Standort in Deutschland, wo man günstige und qualitativ hochwertige Kamagra Ohne Rezept Lieferung in jedem Teil der Welt zu kaufen.

Kaufen priligy im Online-Shop. Wirkung ist gut, kommt sehr schnell, innerhalb von 5-7 Minuten. propecia was nur nicht versucht, verbrachte eine Menge Geld und Nerven, und geholfen hat mir nur dieses Tool.

Leonardminukcvmarch2012

Curriculum Vitae
March 14, 2012
Leonard Minuk
Assistant Professor - Department of Medicine
CONFIDENTIAL DOCUMENT
A. Education and Specialized Training
1. Education
BSc, The University of Manitoba, Medicine, Winnipeg, Manitoba, Canada MD, The University of Manitoba, Medicine, Winnipeg, Manitoba, Canada BSc, University of Winnipeg, Winnipeg, Manitoba, Canada 2. Other Specialized Training
Adult Hematology Subspecialty Clinical Fellowship, University of Western Ontario, London Health Sciences Centre, Hematology, London, Ontario, Canada Internal Medicine Residency, University of Western Ontario, London Health Sciences Centre, Ontario, Canada 3. Qualifications, Certifications and Licenses
Phase Forward Inform 4.6 PI data entry modules, Instruct - Phase Forward, On-line Training 1 - Introduction to GCP 2A - Investigator Responsibilities 2B - Investigator Responsibilities: Informed Consent 3A-Ethics and the Ethics Research Board 3B- Safety Reporting National Cancer Institute of Canada (NCIC) Clinical Trials Group, On-line Training Ethics Training Protecting Human Research Participants, National Institutes of Health (NIH) Office of Extramural Research, On-line Training Fellow of the Royal College of Physicians of Canada (FRCPC), Subspecialty Certificate in Adult Hematology. Royal College of Physicians and Surgeons College of Physician and Surgeons of Ontario (CPSO), Ontario, Canada Fellow of the Royal College of Physicians of Canada (FRCPC), Specialist Certificate in Internal Medicine. Royal College of Physicians of Canada, Canada CONFIDENTIAL DOCUMENT
B. Appointments and Honours
1. Appointments
Current Appointments
Assistant Professor, Department of Medicine, Program of Experimental Medicine, Schulich School of Medicine & Dentistry, The University of Western Ontario Assistant Professor, Department of Medicine, Hematology, Schulich School of Medicine & Dentistry, The University of Western Ontario Assistant Professor, Department of Oncology, Schulich School of Medicine & Dentistry, The University of Western Ontario London Health Sciences Centre, Department of Medicine, Division of Hematology Research and Teaching Appointments
Medical Director, Hematology Clinical Research Unit, London Health Sciences Centre/Lawson Health Research Institute, London, Ontario, Canada Medical Director, Adult Bleeding Disorders Program, London Health Sciences Centre, London, Ontario, Canada Associate Scientist, Lawson Health Research Institute, London, Ontario, Canada 2. Honours
Honours and Awards
Canadian Hematology Society Research Award for Junior Faculty Member, University of Western Ontario, London, Ontario, Canada UWO Department of Medicine Research Day, Best Oral Presentation, University of Western Ontario, London, Ontario, Canada Nominated for Class of Meds ‘49 Award for Excellence in Teaching by Residents (Senior Award), Local, London, Ontario, Canada University of Students’ Council (UWO) Teaching Honour Roll for excellence in teaching in medicine, University of Western Ontario, London, Ontario, Canada Dr. David Meltzer Postgraduate Award in Hematology, London, Ontario, Canada Leonard Kruger Centennial Award for BSc.Med. Research, Canada Midwest Student Biomedical Research Forum Award for BSc. Med. Research Manitoba Medical Services Foundation Award for BSc. Med. research, Winnipeg, Manitoba, Canada Tillie Schwartz memorial Award in Medicine from the Jewish Foundation of Manitoba for high academic standing and community service, Winnipeg, Manitoba, Canada University of Winnipeg Gold Medal for highest academic standing in Biochemistry, Winnipeg, Manitoba, Canada CONFIDENTIAL DOCUMENT
Governor General’s Bronze Medal for highest academic standing in Secondary School, Winnipeg, Manitoba, Canada CONFIDENTIAL DOCUMENT
C. Service and Administration
1. Professional Affiliations and Activities
Professional Associations
Association of Hemophilia Clinic Directors of Canada, Member Peer Review Activities
Canadian Cancer Encyclopedia, Multiple Myeloma Chapter. CONFIDENTIAL DOCUMENT
D. Research and Scholarly Activities
1. Grants and Contracts
Non-Industry
Co-Investigator. Multicentre Canadian Study of Prophylaxis in Older Adults with Severe Hemophilia. Baxter Canadian Hemophilia Epidemiologic Research Program. Funded. $75,000. Co-Investigator. Electrolyte disorders from Common Medications: Risk and Mitigation. Clinical Trial. Canadian Institute of Health Research. Funded. $139,828. Industry
Principal Investigator. A Phase 3 Randomized Open Label Trial of Lenalidomide/dexamethasone with or without Elotuzumab in Subjects with previously untreated Multiple Myeloma CA-204-006. Bristol Myers Squibb. Funded. $10,000. Principal Investigator. A Phase 3 Multicenter Randomized Open Label Study to Compare the Efficacy and Safety of Pomalidomide in combination with Low - Dose Dexamethasone versus High Dose Dexamethasone in subjects with Refractory of Relapsed and Refractory Multiple Myeloma. Celgene Corporation. Funded. $10,000. Principal Investigator. A Phase 3 Randomized Open Label Trial of Lenalidomide/dexamethasone with or without Elotuzumab in Relapsed or Refractory Multiple Myeloma CA204-004. Bristol Myers Squibb. Funded. $10,000. Principal Investigator. An open-label Phase II Study of the efficacy of combination bortezomib-containing regiments in the treatment of newly diagnosed patients with t(4;14) positive multiple myeloma. Funded. Co-Investigator. Alemtuzumab and CHOP Chemotherapy for aggressive histological peripheral T-Cell Lymphomas: A multi-centre Phase I and II Study. Funded. Principal Investigator. An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma. Merck Co. Inc. Funded. $16,036. Principal Investigator. An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma. Merck Co. Inc. Funded. $70,640. Principal Investigator. A phase III, randomized, open-label, 3-arm study to determine the efficacy and safety of Lenalidomide (Revlimid) plus low-dose dexamethasone when given until progressive disease or for 18 four-week cycles versus the combination of Melphalan, Prednisone, and Thalidomide given for 12 six-week cycles in patients with previously untreated Multiple Myeloma who are either 65 years of age or older or not candidates for stem cell transplantation. Celgene Corporation. Funded. $245,253. Co-Investigator. Phase II study of temozolomide in previously untreated acute myeloid CONFIDENTIAL DOCUMENT
leukemia (AML)/myelodysplastic syndrome (MDS) subjects unsuitable for standard induction therapy exhibiting low MGMT expression. Funded. Co-Investigator. A randomized, double-blind, placebo controlled study of the JAK inhibitor INCB 18424 tablets administered orally to subjects with primary myelofibrosis (PMF), post polycythemia Vera-myelofibrosis (PPV-MF) or essential thombocythemia myelofibrosis (PET-MF). Funded. Co-Investigator. A Phase III study of gemcitabine, dexamethasone, and cisplatin compared to dexamethasone, cytarabine and cisplatin plus/minus rituximab [(R)-GDP VS (R)-DHAP] as salvage chemotherapy for patients with relapsed or refractory aggressive histology non-Hodgkin’s lymphoma prior to autologous stem cell transplant and followed up maintenance rituximab versus observation. Funded. Co-Investigator. A randomized, double blind, placebo controlled pilot trial of Rituximab for Adults with immune thrombocytopenic purpura at initial presentation or at relapse following medical treatments who are receiving standard therapy (R-ITP). Funded. CONFIDENTIAL DOCUMENT
E. Publications
1. Peer-Reviewed Publications
Journal Articles
Published
1. Minuk LA, Hsia CC. Refractory anemia with ring sideroblasts masked by iron deficiency anemia. Blood.
2011;117(22):5793. Co-Principal Author
2. Minuk L, Monkman K, Chin-Yee I, Lazo-Langner A, Bhagirath V, Chin-Yee B, Mangel J. Treatment of Hodgkin
Lymphoma with ABVD without routine G-CSF support does not increase the risk of febrile neutropenia. Leukemia
and Lymphoma. 2012; 53(1): 57-63. Principal Author
3. Monkman K, Mahony J, Lazo-Langner A, Chin-Yee B, Minuk L. The pandemic H1N1 influenze vaccine results in low
rates of serovconersion for patients with hematological malignancies. Leukemia and Lymphoma. 2011; 52(9): 1736-
1741. Senior Responsible Author
4. Chin-Yee B, Monkman K, Hussain Z, Minuk L. Attitudes toward Vaccination for Pandemic H1N1 and Seasonal
Influenza in Patients with Hematologic Malignancies. Journal of Supportive Oncology. 2011; 9(4):156-60. Senior
Responsible Author

5. Minuk GY, Hawkins K, Kaita KDE, Wong S, Renner E, Minuk L, Uhanova J. Daily Ciprofloxacin Treatment for
Patients with Advanced Liver Disease Awaiting Liver Transplantation Reduces Hospitalizations. Digestive Diseases
and Science 2011; 56(4):1235-41. Coauthor
6. Minuk L, Sibbald R, Peng J, Bejaimal S, Chin-Yee I. Access to thalidomide for the treatment of multiple myeloma in
Canada: physician behaviours and ethical implications. Current Oncology. 2010; 17(4):11-19. Principal Author
7. Minuk L, Lazo-Langner, Kovacs J, Robbins M, Morrow B, Kovacs M. Normal levels of protein C and protein S tested
in the acute phase of a venous thromboembolic event are not falsely elevated. Thrombosis Journal. 2010;18;8:10.
Principal Author
8. Minuk L, Chin-Yee I, Hibbert A, Chan D, Xenocostas A. Red Blood cell transfusion and chemotherapy
administration:A study of resource utilization. Community Oncology. 2008; 5(11): 598-603. Principal Author
9. Minuk G, Zhang M, gong Y, Minuk L, Dienes H, Kew M, Lipschitz J, Sun D. Decreased hepatocyte membrane
potential differences and GABAa-β3 expression in human hepatocellular carcinoma. Hepatology, 2007; 45:735-45.
Coauthor
Published Abstracts
Published
1. Reece D, Piza Rodriquez G, Szwajcer D, Minuk LA, Pantoja M, Belch A, Shustik C, Stakiw J, White D, Chen C,
Kukreti V, Riedemann R, Sebag M, Trudel S, Jenkins G, W Le L. Bortezomib-based Therapy without Autologous
Stem Cell Transplantation for newly diagnosed multiple myeloma patients with t(4;14): A Canadian National Trial.
American Society of Hematology Annual Meeting, San Diego, California, 2011; Poster #3982. Coauthor
2. Minuk LA, Chin-Yee BH, Louzada ML, Laudenbach L, Chin-Yee IH. The Prevalence of Cardiovascular Risk Factors
in Individuals with Hemophilia. American Society of Hematology Annual Meeting, San Diego, California, 2011;
Abstract #4319. Coauthor
3. Chow K, Monkman K, Gill KS, Minuk L, Mather R. A rare case of corneal crystalline deposits as initial presentation of
multiple myeloma. Canadian Ophthalmological Society Annual Meeting, Vancouver, British Columbia, 2011; Oral
presentation #101. Coauthor
CONFIDENTIAL DOCUMENT
4. Reece D, Piza Rodriquez G, Szwajcer D, Minuk L, Pantoja M, Belch, A, Bahlis N, Shustik C, Stakiw J, White D, Chen
C, Kukreti V, Tiedemann R, Trudel S. Phase II Trial of Bortezombi-Based therapy without ASCT in newly diagnosed
patients with T(4;14) Multiple Myeloma. 13th Annual International Myeloma Workshop Paris, France, 2011; Poster
#220. Coauthor
5. Monkman K, Mahony J, Lazo-Langner A, Chin-Yee B, Chin-Yee I, Minuk L. The Pandemic H1N1 Influenza Vaccine
Results In Low Rates of Seroconversion in Patients with Hematological Malignancies. American Society of
Hematology Annual Meeting, Orlando, Florida, 2010; Poster #3110. Senior Responsible Author
6. Xu J, Minuk LA, Howson-Jan K, Rizkalla K. Case with a complex karyotype including t(8;14) and t(14;18) and
preservation of follicular pattern in a transformed lymphoma. American Society of Human Genetics 59th Annual
Meeting, Honolulu, Hawaii, 2009; Abstract #1272. Coauthor
7. Minuk LA, Lazo-Langner A, Chin-Yee I, Howson-Jan K, Lohmann R, Bhagirath V, Mangel J. Treatment of Hodgkin
Lymphoma with ABVD without routine growth factor support. American Society of hematology Annual Meeting, New
Orleans, Louisiana, 2009; Poster #2502. Principal Author
8. Minuk LA, Eckert K, Charyck-Stewart T, Parry N, Gray D, Chin-Yee I. A trauma transfusion pathway decreases
coagulopathy without increasing blood product utilization. American Society of Hematology Annual Meeting, San
Francisco, California, 2008; Abstract #5619. Principal Author
9. Xu J, Nan S, Munavish D, Chin-Yee I, Barr RM, Minuk LA, Xenocostas A. Complex translocation (8;21:2) a new
translocation (8;21) in acute myeloid leukemia. American Society of Human Genetics Annual Meeting, Salt Lake City,
Utah, 2005. Coauthor
2. Non-Peer-Reviewed Publications
Journal Articles
Published
1. C. Hsia, L. Minuk. What is your opinion about anticoagulation in the elderly? The Canadian Journal of Diagnosis/July
2010. Co-Principal Author
2. C. Hsia, L. Minuk. Managing Leukopenia. How should a persistent leukopenia in an otherwise healthy person be
managed or followed? The Canadian Journal of Diagnosis/July 2010. Co-Principal Author
3. C. Hsia, L. Minuk. Blood Count Differences of Various Nationalities. In a healthy patient of African heritage, who
does not have sickle cell disease (or any other hemoglobinopathy) or the sickle cell trait, how does the complete
blood count (CBC) differ from that of a healthy person of European heritage? when do differences require
investigation? The Canadian Journal of Diagnosis/May 2010. Co-Principal Author
4. C. Hsia, L. Minuk. Blood Type After Allogeneic Bone Marrow Transplant. Why does blood type not change
immediately after an allogeneic bone marrow transplant (i.e. donor type O, recipient type B, now one year post cord
blood transplant for leukemia)? The Canadian Journal of Diagnosis/May 2010. Co-Principal Author
5. C. Hsia, L. Minuk. Sickle Cell Trait. Does the sickle cell trait affect Hgb A1C interpretation? The Canadian Journal of
Diagnosis/May 2010. Co-Principal Author
6. C. Hsia, L. Minuk. Significance of Findings of Chronic Deep Vein Thrombosis. What is the significance of findings of
chronic deep vein thrombosis (DVT) reported on venous Doppler ultrasound? The Canadian Journal of
Diagnosis/February 2010. Co-Principal Author
7. Hsia CC, Minuk LA. Reversing INR Level with Vitamin K. At what INR level is vitamin K urgently required to quickly
reverse the level? Canadian Journal of Diagnosis. 2010;27(3)23. Co-Principal Author
8. Hsia CC, Minuk LA. Common Causes of Low Platelets. What are the most common causes of low platelets in an
otherwise healthy adult? Canadian Journal of Diagnosis. 2010;27(3)30. Co-Principal Author
CONFIDENTIAL DOCUMENT
9. Hsia CC, Minuk LA. Causes of Polycythemia. What are the causes of polycythemia in the general population?
Canadian Journal of Diagnosis. 2010;27(4):27. Co-Principal Author
10. Hsia CC, Minuk LA. Anticoagulation in the Elderly. What is your opinion about anticoagulation in the elderly?
Canadian Journal of Diagnosis. 2010;27(7):24. Co-Principal Author
11. Hsia CC, Minuk LA. Treating Anemia in the Chronically Ill. What is really the treatment for anemia in chronic diseases
(renal failure, cancer, heart failure)? Canadian Journal of Diagnosis. 2010;27(8):24. Co-Principal Author
12. Hsia CC, Minuk LA. Iron Supplements. Please advise on the appropriate therapy of isolated low ferritin. Canadian
Journal of Diagnosis. 2010;27(8):28. Co-Principal Author
13. Hsia CC, Minuk LA. Serum Haptoglobin. What is the significance of serum haptoglobin? Canadian Journal of
Diagnosis. 2010;27(9):24. Co-Principal Author
CONFIDENTIAL DOCUMENT

Source: http://www.bcherp.ca/assets/LeonardMinukCVMarch2012.pdf

Local school nurse is

2013/2014 - Incoming 6th Grade Students Carrie Palmer Weber Middle School Health Information All 6th Grade students born on or after 1/1/94 and who are 11years old are required to have a Tdap (diphtheria, tetanus and pertussis) booster. Documentation of the booster must be brought to the Medical Office by the first day of school in September, 2012. If your child is not 11 years old ye

Smpc-qlaira-5.0a

RESUMEN DE LAS CARACTERÍSTICAS DEL PRODUCTO NOMBRE DEL MEDICAMENTO Qlaira comprimidos recubiertos con película. COMPOSICIÓN CUALITATIVA Y CUANTITATIVA Cada envase calendario contiene 28 comprimidos recubiertos con película, en el siguiente orden: - 2 comprimidos de color amarillo oscuro. Cada comprimido contiene 3 mg de valerato de estradiol - 5 comprimidos de color rojo intermedi

Copyright © 2010-2014 Internet pdf articles